Ipsen

🚨 Breaking News: Ipsen Achieves its Record-High S&P Global Rating! 🚨   We’re thrilled to announce that Ipsen’s rating in the 2024 S&P Global Corporate Sustainability Assessment (CSA) has soared to an all-time high of 61 as of 19 September 2024, placing us in the 94th percentile of our industry! 🌍🚀 This reflects our unwavering commitment to sustainability, transparency, and continuous improvement. With an 87% disclosure rate, we’re leading the way in responsible business practices. 🚀 Together, as #GenerationIpsen, we’re shaping a sustainable future, one milestone at a time. 🌱 Learn more: https://lnkd.in/enpzrq_d #Sustainability #ESG #CorporateResponsibility #BreakingNews 

As Dystonia Awareness Month draws to a close, this new short film by ERN-RND, European Reference Network for Rare Neurological Diseases is a powerful reminder of the challenges faced by people living with this debilitating neurological condition at every stage of disease progression. We are proud that the film was inspired by the patient persona of ‘Lily’, which was created as part of the Cervical Dystonia Patient Experience Map Dystonia Europe published in collaboration with Ipsen: https://lnkd.in/e9C__5Hd

#Ipsen announces the European Commission has approved a new treatment option to manage the intolerable itch experienced by patients from six months old who are living with Alagille Syndrome #Pharma #Investors #Media #RareDiseases #ALGS Learn more: https://lnkd.in/eww8SNbd

🌍 Ipsen’s Commitment to Zero Emissions 🌍  At Ipsen, we are taking decisive action to mitigate climate change and achieve net-zero emissions. Our Generation Ipsen strategy highlights our ongoing efforts and commitment to a sustainable future. Read more here: https://lnkd.in/ez3ZrZvd #ZeroEmissionDay #Sustainability #ClimateAction #NetZero #Ipsen #GenerationIpsen

The European Commission has given approval for a new treatment for the rare liver disease, primary biliary cholangitis (#PBC). With many patients being unresponsive to the current medicines it is great to offer a new treatment choice. #Ipsen #Pharma #RareDiseases #PrimaryBiliaryCholangitis

The European Commission has approved a new treatment for primary biliary cholangitis #PBC. It is the first new medicine for this rare cholestatic liver disease for nearly a decade.  #Ipsen #Pharma #Investors #Media #RareDiseases #PrimaryBiliaryCholangitis Learn more: https://lnkd.in/ezcBZQt9

With new breakthroughs being unveiled, we’re thrilled to see cutting-edge new science first-hand at #ESMO24 in Barcelona. From delivering new innovations today and accelerating exciting new modalities for tomorrow, we’re pushing the boundaries of science for people living with cancer. Learn more: https://lnkd.in/eMpWrhrV

Ipsen announces presentation of new data at #ESMO24 from Phase III CABINET trial in pancreatic and extra-pancreatic neuroendocrine tumors, uncommon forms of cancer which can arise throughout the body #Ipsen #Pharma #ESMO24 #Oncology    Learn more: https://lnkd.in/ex42DpcE

Sandra Silvestri, MD, PhD, Ipsen’s EVP and Chief Medical Officer is discussing the importance of collaboration in #PrimaryBiliaryCholangitis (PBC) this #PBCAwarenessMonth.      Read her article here: https://lnkd.in/ewtbGPXM   #LivingWithPBC #PatientCare 

At Ipsen, we value innovation through diversity 💡. This year, we honor five para-athletes who, by overcoming barriers, inspire our pursuit of impactful excellence for a better and a healthier world 🌍 🏅🌟. Discover the inspiring journeys of Mathieu THOMAS and Gaëlle Edon 👇✨. #InnovationThroughDiversity #ParaAthletes #OvercomingBarriers #Inspiration #Excellence #SportsForAll #ChampionStories #DisabilityAwareness #InclusionMatters #IpsenValues